tirzepatide surpass 2 monotherapy in Chinese patients with early type diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO) SURPASS-2: Tirzepatide bests semaglutide in
Pay in 4 interest-free payments of $7.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16



























